Legit on MSN13d
See more as another foreign company set to leave Nigeria, CEO gives reasons
South African retailer giant Pick n Pay has announced plans to leave Nigeria by selling its stake in A.G. LeventisThe decision comes less than 5 years after it entered the market with so much promise ...
MediaPost19d
CPG Brand Haleon Leads Best Ad Inclusion Rankings, Aims To Improve Even Further
Haleon, the two-year-old CPG spinoff from GSK, is not only leading in marketing inclusion efforts ... It was singled out for a website that discloses the ages and genders of people included ...
Pharmaceutical Technology on MSN2d
Aurinia slashes workforce by 45% to focus on lupus and autoimmune assets
Aurinia has announced a 45% workforce reduction to bolster sales of the lupus drug Lupkynis and advance the development of ...
GEN5d
Patient Dies in Beam Trial of SCD Candidate; Company Cites Conditioning
The patient died four months after BEAM-101 infusion “due to respiratory failure that was determined by the investigator to ...
Zawya12d
AIM Vaccine’s heavyweight single-product mRNA RSV Vaccine obtained the clinical trial approval
HONG KONG SAR - Media OutReach Newswire - 30 October 2024 - AIM Vaccine (06660.HK), the leader in Chinese mRNA vaccines, announced on 30 th October that mRNA respiratory syncytial virus (RSV) vaccine ...
FiercePharma2d
GSK calls it quits on trade group BIO for 2025, following exits by Takeda, UCB and more
GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...
FierceBiotech12d
GSK axes vaccine from $2.1B deal, switching to preclinical successor over 'increased competition'
GSK has stopped (PDF) development of one of the lead programs from its $2.1 billion Affinivax takeover, axing a phase 2 pneumococcal 24-valent vaccine candidate for adults in favor of a ...
Business Insider10d
GlaxoSmithKline Reports Mixed Q3 2024 Results
GlaxoSmithKline (GSK) is a global biopharmaceutical company that focuses on the development and marketing of medicines, vaccines, and healthcare products, with a strong emphasis on innovation in ...
STAT12d
Sales of GSK’s RSV vaccine down dramatically from last year
LONDON — GSK’s once-booming vaccines business met new challenges in the third quarter, as the company lowered sales forecasts for vaccines for the year. Notably, quarterly sales of the ...
Benzinga.com12d
GSK's Q3 Earnings Hit By Lower Than Expected Vaccine Sales, Cautions Lower Revenue For 2024
Also Read: Just After Pfizer’s RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population Specialty Medicine sales increased ...
Bloomberg L.P.13d
GSK Inks Lupus Deal With Chinese Biotech for Up to $850 Million
GSK Plc acquired an experimental drug from Chinese biotech firm Chimagen Biosciences for as much as $850 million, adding to the British drugmaker’s pipeline of potential treatments for lupus.
Seeking Alpha11d
GSK plc (GSK) Q3 2024 Earnings Call Transcript
Welcome to today's call and webcast. The Q3 presentation was sent to our distribution list by e-mail and you can also find it on gsk.com. Please turn to Slide 2. This is the usual safe harbor ...